Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05839392

Novel Approaches to Target MECOM/EVI1 in AML

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

AML, Adult Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ematologia

Piacenza, Italy

Location status: Recruiting

Location contact

Vallisa

CONTACT

About this study

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • AML with MECOM or atypical 3q26 rearrangements.
  • Age ≥18.
  • Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion criteria

  • None

Treatment and study plan

Biological characterization of AML with MECOM or atypical 3q26 rearrangements

Biological

Peripheral blood and bone marrow withdrawal

Primary outcomes

  1. Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable

    Time frame: At baseline

    To assess the number of regulators or effectors of MECOM/EVI1

Study contacts

Contact information is provided by the study sponsor or research team.

Enrico Crea

CONTACT

[email protected]

0670390514

Paola Fazi

CONTACT

[email protected]

0670390528

Sponsors and collaborators

Lead sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Other

Registry information

Official study title

Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 3, 2023
Registry last updated
Dec 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.